Abstract
Human complex I (NADH:ubiquinone oxidoreductase; EC 1.6.5.3) is the first and largest multi-protein assembly of the mitochondrial oxidative phosphorylation (OXPHOS) system; the final biochemical cascade of events leading to the production of ATP. The complex consists of 46 subunits, 7 encoded by the mitochondrial DNA and the remainder by the nuclear genome. In recent years, numerous gene mutations leading to an isolated complex I deficiency have been characterized in both genomes. Disorders associated with complex I deficiency (OMIM 252010) mostly lead to multi-system disorders affecting brain, skeletal muscle and the heart. Of these, Leigh syndrome, a progressive fatal encephalopathy symmetrically affecting specific areas of the brain, brainstem and myelin, is the most frequently observed phenotype. Here, we review the current understanding of the cell biological consequences of isolated complex I deficiencies and propose further directions the field needs to take in order to develop rational treatment strategies for these devastating disorders.
Keywords: mitochondria, cell biology, oxidative phosphorylation, leigh disease, complex I, mitochondrial medicine
Current Neurovascular Research
Title: Cell Biological Consequences of Mitochondrial NADH: Ubiquinone Oxidoreductase Deficiency
Volume: 1 Issue: 1
Author(s): Jan A.M. Smeitink, Lambert W.P.J. van den Heuvel, Werner J.H. Koopman, Leo G.J. Nijtmans, Cristina Ugalde and Peter H.G.M. Willems
Affiliation:
Keywords: mitochondria, cell biology, oxidative phosphorylation, leigh disease, complex I, mitochondrial medicine
Abstract: Human complex I (NADH:ubiquinone oxidoreductase; EC 1.6.5.3) is the first and largest multi-protein assembly of the mitochondrial oxidative phosphorylation (OXPHOS) system; the final biochemical cascade of events leading to the production of ATP. The complex consists of 46 subunits, 7 encoded by the mitochondrial DNA and the remainder by the nuclear genome. In recent years, numerous gene mutations leading to an isolated complex I deficiency have been characterized in both genomes. Disorders associated with complex I deficiency (OMIM 252010) mostly lead to multi-system disorders affecting brain, skeletal muscle and the heart. Of these, Leigh syndrome, a progressive fatal encephalopathy symmetrically affecting specific areas of the brain, brainstem and myelin, is the most frequently observed phenotype. Here, we review the current understanding of the cell biological consequences of isolated complex I deficiencies and propose further directions the field needs to take in order to develop rational treatment strategies for these devastating disorders.
Export Options
About this article
Cite this article as:
Smeitink A.M. Jan, van den Heuvel W.P.J. Lambert, Koopman J.H. Werner, Nijtmans G.J. Leo, Ugalde Cristina and Willems H.G.M. Peter, Cell Biological Consequences of Mitochondrial NADH: Ubiquinone Oxidoreductase Deficiency, Current Neurovascular Research 2004; 1 (1) . https://dx.doi.org/10.2174/1567202043480224
DOI https://dx.doi.org/10.2174/1567202043480224 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Spectral Features and In Vitro Antioxidant Study of Nanoscale Solid Dispersions of Different Sizes of Coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) Prepared by Heat Melt and High-pressure Homogenization Method
Current Nanoscience Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Pesticides-induced Cardiovascular Dysfunctions: Prevalence and Associated Mechanisms
Current Hypertension Reviews Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Current Pharmaceutical Design Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Mitochondria Damage in the Pathogenesis of Diabetic Retinopathy and in the Metabolic Memory Associated with its Continued Progression
Current Medicinal Chemistry Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Uncontrolled Hypertension and Oncology: Clinical Tips
Current Vascular Pharmacology Selectivity Problems with Drugs Acting on Cardiac Na<sup>+</sup> and Ca<sup>2+</sup> Channels
Current Medicinal Chemistry Wogonin and Alleviation of Hyperglycemia <i>via</i> Inhibition of DAG Mediated PKC Expression. A Brief Insight
Protein & Peptide Letters Synthesis, Docking and Antidiabetic Activity of Some Newer Benzamide Derivatives as Potential Glucokinase Activators
Letters in Drug Design & Discovery Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets Stem Cell-Derived Microvesicles: A Cell Free Therapy Approach to the Regenerative Medicine
Current Biotechnology Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Treating Cancer in Older and Oldest Old Patients
Current Pharmaceutical Design Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery